Upsher-Smith Laboratories, Inc
For nearly 100 years, Upsher-Smith Laboratories has been a partner in health care, striving to deliver high-value, high-quality therapies and solutions that measurably improve individuals’ lives. As a family-owned pharmaceutical company, Upsher-Smith is able to adapt and thrive in a dynamic health care environment by continually addressing the ever-changing needs of pharmacists, patients, physicians, and health care organizations. Where there is a need, the company will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life.
The story began in 1919, when English-born pharmacist and chemist Frederick Alfred Upsher Smith started a company to refine digitalis. Operating from a laboratory in Minneapolis, the company’s great innovation was to deliver digitalis in a standardized potency—with consistency in dosage and quality from one batch to the next—an advancement never before achieved in the 134 years since the drug’s discovery. Upsher Smith gave new life to an old drug, and physicians and pharmacists throughout North America ensured that this improved medication benefited thousands of people.
Expanding the Portfolio of Quality Generics
Today, Upsher-Smith’s portfolio includes more than 35 quality generic prescription products with over 300 SKUs. The company continues to actively build this portfolio with a focus on driving measurable value, in dollars and outcomes, within the health care system. As an example, Upsher-Smith’s release of an authorized generic in the testosterone replacement therapy market, in multiple configurations, offers increased options and access for patients. This commitment to quality and cost-effective products, coupled with the highest level of customer support, has helped make Upsher-Smith a trusted name in the US generics marketplace.
Upsher-Smith: The Future
Upsher-Smith continues to build its broad portfolio of generic drugs from its headquarters in Minnesota, as well as in its satellite facilities. The company is also focused on developing medications for people affected by neurological disorders, with a pipeline of central nervous system compounds. While the company’s lead compounds are focused on seizure disorders, Upsher-Smith is also exploring potential treatments for Parkinson’s disease, cognitive deficits, neuropathic pain, and inflammatory conditions.
For more information, visit http://www.upsher-smith.com.